Diaceutics's ROE % for the quarter that ended in Dec. 2025 was 12.68%. Diaceutics's PB Ratio for the quarter that ended in Dec. 2025 was 2.60.
Diaceutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 4.88%.
Diaceutics ROE % Adjusted to Book Value Related Terms
Diaceutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Diaceutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7DC vs VEEV, BTSG, TEM: ROE % Adjusted to Book Value Comparison
For the Health Information Services subindustry, Diaceutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Diaceutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 4.88% mean?
Diaceutics (FRA:7DC) has a ROE % Adjusted to Book Value of 4.88% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Diaceutics and its competitors.
Is Diaceutics' ROE % Adjusted to Book Value too high?
Diaceutics' current ROE % Adjusted to Book Value is 4.88%. Overall, Diaceutics has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' ROE % Adjusted to Book Value compare to VEEV and BTSG?
Diaceutics' ROE % Adjusted to Book Value of 4.88% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Diaceutics and its competitors. Diaceutics's current ROE % Adjusted to Book Value is 4.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (FRA:7DC) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.13, compared to a current price of €1.64 — trading 23% below its estimated fair value. The current ROE % Adjusted to Book Value is 4.88%. Diaceutics' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Diaceutics (FRA:7DC), the current ROE % Adjusted to Book Value is 4.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (FRA:7DC) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of €1.64 is trading 23% below its estimated GF Value™ of €2.13.
GuruFocus considers Diaceutics to be Modestly Undervalued.
Key valuation signals for FRA:7DC:
ROE % Adjusted to Book Value: 4.88%
GF Value™: €2.13 vs. price of €1.64 (23% below fair value)
No single metric tells the full story. See the FRA:7DC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
90GF Score
Get the complete analysis for FRA:7DC
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7DC has been successfully added to your 
